Critique Pembrolizumab (Keytruda): CADTH Reimbursement Advice: Indicator: Together with chemotherapy, with the cure of Grownup sufferers with locally recurrent unresectable or metastatic triple-adverse breast most cancers who've not acquired prior chemotherapy for metastatic illness and whose tumours express programmed mobile Dying-ligand one (comb